Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1060965

	registered interest
	date	14/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Counselling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has to ensure that people with cancer are able to access psychological and emotional support.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	909320
	answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>By 2021, every person diagnosed with cancer will have access, where appropriate, to personalised care, including a needs assessment, a care plan and health and wellbeing information and support. The needs assessment guides a conversation about the person’s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns, including psychological and emotional.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/02/2019 17:25:31 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1050101

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asparaginase
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 January 2019 to Question 207238 on Asparaginase, what steps Porton Biopharma will take to increase capacity of erwinase and better supply the (a) UK and (b) world market for the remainder of 2019.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	213322
	answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Porton Biopharma Ltd (PBL) are implementing a series of initiatives to increase capacity and supply in both the short and long term. These include the following:</p><p>- Extending operational activities to 24 hours a day, seven days a week to maximise fermentation of the product;</p><p>- Implementing an ongoing capital programme including construction of a new pharmaceutical fermentation facility. The facility was completed in April 2018 and is currently undergoing testing; it has an increased capacity fermentation suite which will enable PBL to manufacture at larger scale and is due to start producing product Q3 2019 for regulatory approval to market;</p><p>- A new filling and freeze-drying building was completed in February 2016. The installation of a new filling line which covers the entire process, including vial washing, filling, stoppering and freeze drying. The new line has been designed with systems which monitor all critical parameters throughout the process to accelerate batch release and will accommodate increased capacity. The beneficial use of this and the fermentation facility will coincide to maximise increased product output; and</p><p>- Sourcing replacement suppliers, including for new stoppers and new vials for the product, ensuring that maximum batch sizes can be achieved with minimal product rejects. This programme is complete.</p><p> </p><p>PBL has made significant investments into increasing product capacity and will continue to release future batches as soon as they become available to Jazz Pharmaceuticals (who are responsible for the packaging/distribution and allocation of worldwide product supply).</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:09:48 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1050100

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 March 2018 to Question 134294 on Haematological Cancer, when he plans for the evaluation of the rapid diagnostic centres to be published; and he plans for that evaluation to inform the national roll-out of the centres as proposed in the NHS Long-Term Plan.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	213321
	answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Ten multi-disciplinary diagnostic centres are being piloted through the Accelerate, Co-ordinate, Evaluate (ACE) partnership between Cancer Research UK, Macmillan Cancer Support and NHS England. This pilot programme will end in March 2019. Early findings from those sites informed the plans for roll out of the Rapid Diagnostic Centres as part of the NHS Long Term Plan.</p><p> </p><p>During 2019/20, the ACE Programme will share further evaluation from the pilot centres. The findings will continue to inform plans for expansion of the Rapid Diagnostic Centres, alongside work being led by Cancer Alliances to improve early diagnosis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:31:33 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1039028

	registered interest
	date	10/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asparaginase
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether Erwinase will be available for the treatment for children with acute lymphoblastic leukaemia between January 2019 and March 2019; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	207238
	answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed by Jazz Pharmaceuticals under a global licencing agreement.</p><p> </p><p>Due to increased demand for Erwinase and because PBL are manufacturing at capacity, until increases in capacity are brought into beneficial use there will be occasional stock-outs.</p><p> </p><p>The product is currently in stock in the United Kingdom. The Department has been informed, it is likely there will be a short stock-out in early February 2019 and then a further batch is planned to be released to Jazz Pharmaceuticals, who are responsible for the packaging/distribution and allocation of worldwide product supply, anticipated to reach the UK market by mid-February 2019 which should last until the end of March 2019.</p><p> </p><p>The Department and Public Health England (PHE) are in close contact with, and have been kept informed by the PBL management of short periods of interrupted supply. PBL have and will be implementing a series of initiatives to increase capacity and better supply the market in both the short and long term. PBL are fully aware of the consequences that the unavailability of Erwinase has on patients and are absolutely committed to working with all involved to resolve any issues and be able to supply this critical medicine.</p><p> </p><p>The Department and PHE will continue to monitor the situation closely.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2019 12:18:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1017502

	registered interest
	date	30/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of (a) leukaemia, (b) non-Hodgkin lymphoma, (c) Hodgkin lymphoma and (d) myeloma cases were diagnosed at each cancer stage in each of the last five years.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	197620
	answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>This information is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/12/2018 15:38:39 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1002558

	registered interest
	date	06/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of the NHS long-term plan to (a) tackle the evolving challenges of cancer and (b) ensure that people are able to access personalised and tailored support after they have finished cancer treatment itself.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	188796
	answer	answer is ministerial correction date of answer 14/11/2018 answer text <p>The NHS Long Term Plan provides an excellent opportunity to look at how cancer and other services can be further improved over the next decade. The plan is currently in development and will be published later in the year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/11/2018 11:29:49 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

994628

	registered interest
	date	25/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS England news releases of 5 September and 5 October, when he plans to make CAR-T cell therapy available to (a) people aged under 25 with acute lymphoblastic leukaemia and (b) adult patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after two or more previous therapies have failed.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	183918
	answer	answer is ministerial correction date of answer 02/11/2018 answer text <p>NHS England is working with the manufacturers and National Health Service providers to prepare the NHS to begin delivering Chimeric Antigen Receptor T Cell (CAR-T) therapy - the first in a wave of treatments in a new era of personalised medicine and part of the NHS’s long-term plan to upgrade cancer service. The first treatment that will be available to patient is tisagenlecleucel (Kymriah) as an option for treating children and young people up to 25 years old with B cell acute lymphoblastic leukaemia that is refractory, in relapsed post-transplant or in second or later relapse.</p><p> </p><p>NHS England anticipates that the National Institute for Health and Care Excellence will recommend this treatment for entry into the Cancer Drugs Fund in mid-November. If so, funding will be made immediately available, following a successful commercial deal with the manufacturer Novartis. We anticipate the first patients will begin their treatment in late November 2018. The phased implementation required by the manufacturer and the NHS means that full capacity to treat eligible patients will take some months to achieve and a National CAR-T Clinical Panel will convene in mid-November to assure equity of access and prioritise eligible patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 02/11/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

987817

	registered interest
	date	15/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the initiatives announced by the Prime Minister on 3 October 2018 on early detection rates for cancer include blood cancer; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	179183
	answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>NHS England is completely clear that the new 75% early diagnosis ambition announced by the Prime Minister covers all cancers, and not just the 10 currently included in the Public Health Outcomes Framework (PHOF) early diagnosis metric. NHS England is keen to work with the voluntary sector organisations and charities representing some of the other cancers not currently included in the PHOF metric on how we best measure progress towards the ambition moving forwards.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:57:18 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

982661

	registered interest
	date	08/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many blood cancer patients have received medicine funded by the Cancer Drugs Fund by each medicine since 2016.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	176228
	answer	answer is ministerial correction date of answer 16/10/2018 answer text <p>We have been informed by NHS England that since the implementation of the new Cancer Drugs Fund on 29 July 2016, 7,821 patients have been registered to receive treatment for a blood cancer, out of a total of approximately 25,700 patients who have been registered to receive cancer drug treatment. NHS England has advised that it is unable to provide a breakdown of patients registered to receive treatment with each medicine for reasons of commercial confidentiality.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/10/2018 16:10:46 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

746126

	registered interest
	date	28/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects the Cancer Transformation Fund to be made available to support the Cancer Recovery Package and the cancer stratified follow-up pathways.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	1543
	answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>In December 2016, Cancer Alliances were invited to submit bids against a £200 million transformation fund (for 2017/18 and 2018/19) to support delivery of early diagnosis and implementation of the Recovery Package and stratified follow-up pathways. Based on an assessment of the bids, NHS England has decided to take a phased approach to releasing the funding over the course of 2017/18.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2017 11:22:52 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

917382

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which Cancer Alliances Groups are providing the cancer recovery package; and whether it is being provided to all people diagnosed with cancer in those areas.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150008
	answer	answer is ministerial correction date of answer 12/06/2018 answer text <p>Psychological support for cancer is a specialised area and is often offered within cancer teams via health psychology teams. Adults experiencing all forms of cancer are able to access Improving Access to Psychological Therapies services which provide evidence-based psychological therapies for people with anxiety disorders and depression. Recovery Package interventions will help ensure patients have more personal care and support from the point they are diagnosed. Two of the key interventions within the Recovery Package, the Health Needs Assessment and Care Plans, will enable patients to be sign-posted or referred to psychological support, where necessary.</p><p> </p><p>Personalised follow up and support to help people live well with and beyond cancer is one of the key strategic priorities in the Cancer Strategy for England, which aims to create world class cancer services. NHS England will roll out Recovery Package interventions nationally by 2020 so they are available to all cancer patients across the country regardless of location. All Cancer Alliances are receiving funding in 2018/19 to support implementation of the Recovery Package.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 150006 question first answered 12/06/2018 15:19:16 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

917381

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ibrutinib
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care how many people have received Ibrutinib on the NHS for the treatment of relapsed or refractory chronic lymphocytic leukaemia since January 2017.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150007
	answer	answer is ministerial correction date of answer 13/06/2018 answer text <p>The information requested is not available. The number of patients registered to receive treatment with ibrutinib for relapsed or refractory chronic lymphocytic leukaemia between 1 January 2017 and 31 May 2018 was 976. Patients registered to receive a treatment do not then necessarily go on to receive treatment with a drug.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/06/2018 15:32:47 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

917380

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether access to psychological support under the Cancer Recovery Package will be provided through the Improving Access to Psychological Therapies pathway for people with long-term physical health conditions.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150006
	answer	answer is ministerial correction date of answer 12/06/2018 answer text <p>Psychological support for cancer is a specialised area and is often offered within cancer teams via health psychology teams. Adults experiencing all forms of cancer are able to access Improving Access to Psychological Therapies services which provide evidence-based psychological therapies for people with anxiety disorders and depression. Recovery Package interventions will help ensure patients have more personal care and support from the point they are diagnosed. Two of the key interventions within the Recovery Package, the Health Needs Assessment and Care Plans, will enable patients to be sign-posted or referred to psychological support, where necessary.</p><p> </p><p>Personalised follow up and support to help people live well with and beyond cancer is one of the key strategic priorities in the Cancer Strategy for England, which aims to create world class cancer services. NHS England will roll out Recovery Package interventions nationally by 2020 so they are available to all cancer patients across the country regardless of location. All Cancer Alliances are receiving funding in 2018/19 to support implementation of the Recovery Package.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 150008 question first answered 12/06/2018 15:19:16 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

917379

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the General Practice Forward View, what estimate he has made of the number of people with blood cancer that will have access to the 3,000 mental health therapists co-located in GP surgeries; and whether those therapists will be provided with specific training on blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150005
	answer	answer is ministerial correction date of answer 12/06/2018 answer text <p>No such estimate has been made. Mental health therapists are not specifically trained on blood cancer as a condition, however cancer as a general condition forms part of the training which aims to enable experienced psychological well-being practitioners and high intensity therapists to deliver National Institute for Health and Care Excellence recommended treatments for people presenting to Improving Access to Psychological Therapies services with long-term physical conditions such as diabetes, cardiac disease, respiratory disease, and cancer with accompanying low mood and/or anxiety. The training focuses on high intensity and low intensity approaches to support people with mental health problems and physical long-term conditions or persistent and distressing medically unexplained symptoms.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/06/2018 15:23:42 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

917378

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what plans he has to make an assessment of the effectiveness of the Improving Access to Psychological Therapies pathway for people with long-term health conditions for people affected by blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150004
	answer	answer is ministerial correction date of answer 12/06/2018 answer text <p>NHS England has not specified estimates of individual conditions for referral into the Improving Access to Psychological Therapies (IAPT) integrated pathway. Local commissioning groups decide which pathways they integrate with based on their local prevalence and local intelligence data.</p><p> </p><p>Similarly, the NHS Digital IAPT dataset does not collect information on patients with a diagnosis of cancer, or types of cancer.</p><p> </p><p>There are currently no national plans to assess the effectiveness of the IAPT long-term health conditions pathway on people affected specifically by blood cancer. However there is robust evidence that by using the National Institute for Health and Care Excellence approved psychological therapies in addressing the mental health issues of those people with long term conditions earlier, talking therapies help to improve patients’ health outcomes so that they become less reliant on primary and emergency care and importantly, help patients to self-manage their long-term conditions more confidently.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 150002 150003 question first answered 12/06/2018 13:56:50 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

917377

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans NHS Digital has to publish information on the types of cancer referred into the Improving Access to Psychological Therapies (IAPT) pathway for people with long-term health conditions in the statistical releases entitled, Psychological therapies: reports on the use of IAPT services.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150003
	answer	answer is ministerial correction date of answer 12/06/2018 answer text <p>NHS England has not specified estimates of individual conditions for referral into the Improving Access to Psychological Therapies (IAPT) integrated pathway. Local commissioning groups decide which pathways they integrate with based on their local prevalence and local intelligence data.</p><p> </p><p>Similarly, the NHS Digital IAPT dataset does not collect information on patients with a diagnosis of cancer, or types of cancer.</p><p> </p><p>There are currently no national plans to assess the effectiveness of the IAPT long-term health conditions pathway on people affected specifically by blood cancer. However there is robust evidence that by using the National Institute for Health and Care Excellence approved psychological therapies in addressing the mental health issues of those people with long term conditions earlier, talking therapies help to improve patients’ health outcomes so that they become less reliant on primary and emergency care and importantly, help patients to self-manage their long-term conditions more confidently.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 150002 150004 question first answered 12/06/2018 13:56:50 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

917376

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people with blood cancer that will be referred into the Improving Access to Psychological Therapies integrated pathway as a result of the NHS Digital pilot data, published on 10 May 2018.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150002
	answer	answer is ministerial correction date of answer 12/06/2018 answer text <p>NHS England has not specified estimates of individual conditions for referral into the Improving Access to Psychological Therapies (IAPT) integrated pathway. Local commissioning groups decide which pathways they integrate with based on their local prevalence and local intelligence data.</p><p> </p><p>Similarly, the NHS Digital IAPT dataset does not collect information on patients with a diagnosis of cancer, or types of cancer.</p><p> </p><p>There are currently no national plans to assess the effectiveness of the IAPT long-term health conditions pathway on people affected specifically by blood cancer. However there is robust evidence that by using the National Institute for Health and Care Excellence approved psychological therapies in addressing the mental health issues of those people with long term conditions earlier, talking therapies help to improve patients’ health outcomes so that they become less reliant on primary and emergency care and importantly, help patients to self-manage their long-term conditions more confidently.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 150003 150004 question first answered 12/06/2018 13:56:50 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

904118

	registered interest
	date	14/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ibrutinib
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the interpretation by NHS England of NICE guidance on the level of provision of Ibrutinib for patients with chronic lymphocytic leukaemia.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	143739
	answer	answer is ministerial correction date of answer 21/05/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) published guidance recommending ibrutinib for use in the treatment of previously treated chronic lymphocytic leukaemia and previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation in January 2017. NHS England is legally required to fund drugs and treatments recommended in NICE technology appraisal guidance in line with NICE’s recommendations.</p><p> </p><p>NICE has not been able to make a recommendation on the use of ibrutinib for use in the treatment of other patients with chronic lymphocytic leukaemia because no evidence submission was received from the product’s manufacturer. Ibrutinib is not therefore routinely commissioned for National Health Service patients for these other indications. NICE will review this decision if the company decides to make an evidence submission.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 144154 question first answered 21/05/2018 15:59:46 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

896513

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of funding for providing new treatments for blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	140701
	answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>In England there is a well-established framework for enabling access to cost effective new cancer medicines. All new licensed cancer medicines are referred to the National Institute for Health and Care Excellence (NICE) for inclusion within the Technology Appraisal Programme. This referral is irrespective of the clinical indication concerned. Where cancer medicines are approved by NICE for use in England, NHS England makes these available immediately. NICE now also has the ability to refer licensed medicines demonstrating promising, but not yet certain, benefits for inclusion within the Cancer Drugs Fund.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/05/2018 15:37:08 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

896511

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what support his Department provides to people diagnosed with blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	140700
	answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>The Recovery Package is designed to help patients and clinicians assess a patient’s holistic needs and plan appropriately for their care and support. It includes a Holistic Needs Assessment (HNA) and Care Plan. This guides a conversation about the person’s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns. An HNA should take place within 31 days of diagnosis and at the end of each acute phase of treatment and the Care Plan updated each time. The Recovery Package is being commissioned and delivered in full or in part by many clinical commissioning groups and providers across England. Our aim now is to accelerate the process, to ensure full implementation by 2020 - available to all cancer patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 140697 140698 question first answered 14/05/2018 11:25:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

896509

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to widen the cancer dashboard to include blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	140699
	answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>Public Health England and NHS England developed the first iteration of the cancer dashboard in response to recommendations in the Independent Cancer Taskforce report ‘Achieving world-class cancer outcomes: a strategy for England 2015-2020’. This includes data on breast, colorectal, lung and prostate cancers. Further cancer sites, including blood cancer, were not included because of the risk of making patients identifiable when viewing data for individual hospitals or clinical commissioning groups.</p><p> </p><p>A second iteration of the dashboard is being considered by the National Cancer Transformation Board with a wider ambition to include rarer cancers and cancers with a lower incidence, such a blood cancers, as the dashboard develops.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/05/2018 11:28:20 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

896508

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the cancer recovery package meets the needs of people with blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	140698
	answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>The Recovery Package is designed to help patients and clinicians assess a patient’s holistic needs and plan appropriately for their care and support. It includes a Holistic Needs Assessment (HNA) and Care Plan. This guides a conversation about the person’s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns. An HNA should take place within 31 days of diagnosis and at the end of each acute phase of treatment and the Care Plan updated each time. The Recovery Package is being commissioned and delivered in full or in part by many clinical commissioning groups and providers across England. Our aim now is to accelerate the process, to ensure full implementation by 2020 - available to all cancer patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 140697 140700 question first answered 14/05/2018 11:25:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

896506

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that (a) emotional and (b) psychological support is provided to people who have blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	140697
	answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>The Recovery Package is designed to help patients and clinicians assess a patient’s holistic needs and plan appropriately for their care and support. It includes a Holistic Needs Assessment (HNA) and Care Plan. This guides a conversation about the person’s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns. An HNA should take place within 31 days of diagnosis and at the end of each acute phase of treatment and the Care Plan updated each time. The Recovery Package is being commissioned and delivered in full or in part by many clinical commissioning groups and providers across England. Our aim now is to accelerate the process, to ensure full implementation by 2020 - available to all cancer patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 140698 140700 question first answered 14/05/2018 11:25:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

896505

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure people with blood cancer are diagnosed as soon as possible.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	140696
	answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>Early diagnosis of blood cancers is difficult as symptoms, such as tiredness or back pain, are often misdiagnosed. For suspected blood cancers, the National Institute for Health and Care Excellence published a revised guideline in 2015 which clearly sets out that general practitioners should consider a very urgent full blood count within 48 hours to assess for leukaemia if adults present with suspicious symptoms.</p><p> </p><p>In December 2016 NHS England announced transformation funding of £200 million for Cancer Alliances to encourage new and innovative ways to diagnose cancer earlier, improve the care for those living with cancer and ensure that each cancer patient gets the right care for them.</p><p> </p><p>Additionally, the Accelerate, Coordinate and Evaluate Programme is a unique early diagnosis initiative, a programme of 60 projects exploring innovative concepts of diagnosing cancer earlier across England. The programme is testing a new multi-disciplinary diagnostic centre approach to diagnosing patients with vague or unclear but concerning symptoms, often characteristic of hard to diagnose cancers like blood cancers.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/05/2018 11:23:24 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872380

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 March 2018 to Question 132100, on Haematological Cancer, whether he or NHS England plan to publish information on the work of multidisciplinary diagnostic centres before December 2018.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134294
	answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The 10 multidisciplinary diagnostic centres or ‘rapid assessment and diagnostic centres’ have been described in the Progress Report on the cancer strategy published by NHS England in October 2017 at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf</a></p><p> </p><p>The evaluation of the centres is being undertaken by the Accelerate, Co-ordinate, Evaluate Partnership, which will publish its final report in December 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:55:02 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872376

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Nurses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether every patient diagnosed with cancer receives support from a clinical nurse specialist; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134290
	answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Cancer Patient Experience Survey 2016 results show that 90% of respondents said that they were given the name of a clinical nurse specialist who would support them through their treatment. NHS England is working alongside Health Education England to expand the number of Clinical Nurse Specialists (CNS) and develop clear CNS competencies and routes into training. This will ensure every cancer patient has access to a CNS or other support worker by 2021.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:56:27 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872375

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 March 2018 to Question 132195, on Haematological Cancer: Mental Health Services, whether patients diagnosed with blood cancer but not yet starting treatment will be eligible for the Cancer Recovery Package.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134289
	answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>Every cancer patient will be eligible for the Recovery Package intervention regardless of their treatment status.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:57:20 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872374

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people have accessed the Cancer Recovery Package in the last 12 months; and what proportion of those people had blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134288
	answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>This information is not held centrally. NHS England is currently developing plans for national data collection.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 14:00:43 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872373

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what drugs have been funded through the Cancer Drugs Fund this year; and how much funding remains in that Fund.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134287
	answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>Since April 2017, there are currently 27 drugs in 42 indications that are funded by the Cancer Drugs Fund (CDF). A full list of current and previous CDF drugs can be viewed at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/" target="_blank">https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/</a></p><p> </p><p>The latest published spend for the first six months of 2017/18 implies a circa £76 million of unused funding for that period against the CDF. The quarterly activity report is a snapshot of CDF spend at a point in time and the spend figure will increase as more drugs are added to the fund. The link to the report can be found here:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:51:19 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872275

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) NHS England and (b) NICE on the development of (a) multi-indication pricing, (b) outcomes-based pricing and (c) annuity deals for new treatments.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134189
	answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Department has regular and ongoing dialogue with NHS England and the National Institute for Health and Care Excellence on matters related to medicines pricing and patient access to new treatments. We will consider all relevant issues in upcoming discussions with the pharmaceutical industry on medicines pricing arrangements for 2019 onwards to succeed the current Pharmaceutical Price Regulation Scheme.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 14:02:10 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872274

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer and Rare Diseases: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NICE appraisals for new treatments for rare (a) diseases and (b) cancers.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134188
	answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>Most new drugs and significant licence indications are assessed by the National Institute for Health and Care Excellence (NICE) through its technology appraisal programme, through which NICE has been able to recommend a significant number of drugs for the treatment of rare cancers and other diseases for routine use on the National Health Service. NICE also operates a separate Highly Specialised Technology evaluation programme for the evaluation of a very small number of treatments for very rare diseases.</p><p>The methods and processes NICE uses in the development of its guidance are internationally respected, have been developed through extensive engagement with a full range of stakeholders, including the Department, and are regularly reviewed to ensure that they remain fit for purpose.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/04/2018 13:25:57 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872273

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with Refractory B-cell Acute Lymphoblastic Leukaemia have been unable to access treatments for that condition.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134187
	answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134186 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

872272

	registered interest
	date	26/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	134186
	answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134187 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

860743

	registered interest
	date	12/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what proportion of patients referred to a multidisciplinary diagnostic centre have been (a) suspected of having blood cancer and (b) diagnosed with blood cancer; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	132100
	answer	answer is ministerial correction date of answer 19/03/2018 answer text <p>An evaluation is currently being prepared on the work of the multi-disciplinary diagnostic centres, which will include further information on blood cancer patient referral and diagnosis numbers. A final report will be published in December 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/03/2018 15:32:36 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

837754

	registered interest
	date	06/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the most recent results of the National Cancer Patient Experience Survey, what steps (a) his Department and (b) NHS England are taking to improve the training for healthcare professionals to ensure that people with blood cancer understand their diagnosis.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126785
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>Health Education England, alongside NHS England, has recently published the Cancer Workforce plan, which sets out the steps to transform the cancer workforce in line with the independent cancer taskforce recommendations. This will aim to improve patient outcomes and deliver a better patient experience across all tumour types, including haematological cancers. The report sets out the plan for improving the training of healthcare professionals, as well as recruitment and retention plans. The report can be found at:</p><p><a href="https://www.hee.nhs.uk/news-blogs-events/hee-news/health-education-england-unveils-plan-transform-future-nhs-cancer-workforce" target="_blank">https://www.hee.nhs.uk/news-blogs-events/hee-news/health-education-england-unveils-plan-transform-future-nhs-cancer-workforce</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 15:29:34 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836022

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many NHS specialist haematological cancer posts have been vacant in each of the last five years; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126377
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>The information is not available in the format requested.</p><p> </p><p>In December Health Education England published a cancer workforce plan for England which sets out how the National Health Service will ensure it has access to the cancer workforce it needs to 2021. The cancer workforce plan is available at the following link:</p><p> </p><p><a href="http://www.hee.nhs.uk/sites/default/files/documents/Cancer%20Workforce%20Strategy%20Graphs%20and%20tables%20FINAL.pdf" target="_blank">www.hee.nhs.uk/sites/default/files/documents/Cancer%20Workforce%20Strategy%20Graphs%20and%20tables%20FINAL.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 15:37:09 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836021

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the National Institute for Health and Clinical Excellence guidance, Haematological cancers: Improving outcomes (NG 47); and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126376
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>Currently there has been no assessment of NG47.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 14:38:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836020

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to include blood cancer diagnoses as part of the cancer dashboard.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126375
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>Public Health England and NHS England developed the first iteration of the cancer dashboard in response to recommendations in the Independent Cancer Taskforce report ‘Achieving world-class cancer outcomes: a strategy for England 2015-2020’. This includes data on breast, colorectal, lung and prostate cancers. Further cancer sites (including blood cancer) were not included because of the risk of making patients identifiable when viewing data for individual hospitals or clinical commissioning groups.</p><p> </p><p>A second iteration of the dashboard is being developed by NHS Digital and NHS England with a wider ambition to include rarer cancers and cancers with a lower incidence, such a blood cancers, as the dashboard develops.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 14:41:34 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836019

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of people diagnosed with blood cancer have had access to a clinical nurse specialist in each of the last three years; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126374
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>NHS England does not collect this information centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 14:39:50 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836018

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether diagnostic centres established as a result of the Cancer Strategy for England take specific account of blood cancer; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126373
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>The wave two of the Accelerate, Coordination and Evaluation (ACE) programme is testing a new multi-disciplinary diagnostic centre approach to diagnosing patients with vague or unclear but concerning symptoms, often characteristic of hard to diagnose cancers like blood cancers. This approach aims to ensure that patients can receive a suite of tests, reducing the risk that patients receive multiple different referrals for the same problem. The ACE programme has established ten pilot Rapid Diagnostic Assessment Centres across five areas of the country.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/02/2018 15:33:52 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836017

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of trends in the instances of blood cancer being diagnosed after an emergency admission; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126372
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>In 2015, the latest year for which data are available, the percentage of patients diagnosed after an emergency presentation in England for all blood cancers was 28% (7,626 of 26,869).</p><p> </p><p>There has been a fall in the percentage diagnosed through this emergency presentation route over the last 10 years for some of these cancers: chronic lymphocytic leukaemia (26% in 2006 down to 13% in 2015), multiple myeloma (37% down to 31%), and other haematological malignancies (37% down to 25%). The proportion over time in the other groups remained relatively stable.</p><p> </p><p>As a proportion of all emergency diagnoses, the proportion of blood cancers diagnosed as an emergency was 12% in 2011 and 13% in each of 2012-2015.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 126371 question first answered 08/02/2018 14:30:04 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

836016

	registered interest
	date	02/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many emergency presentations there were of blood cancer; what proportion of those presentations were of all diagnoses of blood cancer; and what proportion those were of the total of all emergency presentations of cancer in each of the last five years for which figures are available.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	126371
	answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>In 2015, the latest year for which data are available, the percentage of patients diagnosed after an emergency presentation in England for all blood cancers was 28% (7,626 of 26,869).</p><p> </p><p>There has been a fall in the percentage diagnosed through this emergency presentation route over the last 10 years for some of these cancers: chronic lymphocytic leukaemia (26% in 2006 down to 13% in 2015), multiple myeloma (37% down to 31%), and other haematological malignancies (37% down to 25%). The proportion over time in the other groups remained relatively stable.</p><p> </p><p>As a proportion of all emergency diagnoses, the proportion of blood cancers diagnosed as an emergency was 12% in 2011 and 13% in each of 2012-2015.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 126372 question first answered 08/02/2018 14:30:04 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

786830

	registered interest
	date	10/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to increase capacity in general practice in (a) Crawley constituency and (b) England.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	112399
	answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>In April 2016, the General Practice Forward View set out a package of investment in general practice. This included a number of reforms which will increase capacity in general practice through recruitment and retention of general practitioners (GPs) and the wider workforce, and investment in extended access to GP services and the Time for Care programme.</p><p> </p><p>By 2020 the Government has committed to 5,000 additional GPs and 5,000 other staff in general practice; and by March 2019 everyone having access to GP services, including sufficient routine appointments at evenings and weekends to meet locally determined demand.</p><p> </p><p>The Time for Care programme will spread awareness of innovations that will help release capacity in general practice and facilitate local change programmes to implement them. Examples of these innovations include active signposting and developing the team. It is estimated that most practices can expect to release about 10% of GP time. The Time for Care programme provides support for groups of practices to implement their choice of the actions. To date, this has covered 115 clinical commissioning groups, available to 3,974 practices.</p><p> </p><p>In 2016/17 £2,000,000 of funding was awarded to NHS Crawley Clinical Commissioning Group to improve local GP practice resilience and sustainability and improve access to local GP services for patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2017 12:25:28 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

765286

	registered interest
	date	06/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Transplant Surgery: Stem Cells
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will discuss with NHS England the necessity for a review of the care and support that patients receive after a stem cell transplant.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	105453
	answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Post-transplant care for patients is important. NHS England’s Specialised Commissioning team and Clinical Reference Group for Blood and Marrow Transplants (BMT) are undertaking work to map care needs post-100 days.</p><p> </p><p>There are no current plans to review the responsibilities of services commissioned by NHS England and clinical commissioning groups (CCGs) for BMT at this time. NHS England will be assessing BMT in more detail over the next 18 months and will take the opportunity to further support improved pathway planning and commissioning of services that it and CCGs fund.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/10/2017 16:36:57 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

765287

	registered interest
	date	06/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Transplant Surgery: Stem Cells
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, for what reason responsibility for commissioning services following a stem cell transplant from NHS England to clinical commissioning groups after 100 days.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	105452
	answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>The Manual for Prescribed Specialised Services describes which elements of specialised services are commissioned by NHS England and which are commissioned by clinical commissioning groups (CCGs):</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/10/prescribed-specialised-services-manual-2.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/10/prescribed-specialised-services-manual-2.pdf</a></p><p>Due to the small number of patients involved, the cost of the transplant episode and the small number of transplant experts, Blood and Bone Marrow Transplantation (BMT) is defined as a prescribed specialised service. NHS England is responsible for commissioning and funding the transplant related care which takes place 30 days before transplant and continues until 100 days post-transplant. After 100 days post-transplant, commissioning responsibility for the routine follow-up of patients switches from NHS England to CCGs, as outlined in the Manual.</p><p>In the event that transplant patients experience serious complications post-transplant, elements of their care would likely continue to be planned, organised and funded by NHS England specialised commissioning. For example, if a patient requires Extracorporeal Photopheresis which is a treatment for acute and chronic graft versus host disease following transplantation, NHS England commissions this care post-transplant.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/10/2017 16:39:07 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith